Lazydaze

Lazydaze is a clinical-stage biotechnology company focused on the development of a new class of non-opioid analgesics for the treatment of chronic and acute pain. Founded by Nobel laureate David Julius and renowned neuroscientist Allan Basbaum, the company leverages deep expertise in the molecular mechanisms of pain signaling, particularly the role of TRP channels. Their lead programs aim to provide effective pain relief without the addictive properties or side effects associated with traditional opioid therapies. By targeting specific sensory pathways, Lazydaze seeks to transform the landscape of pain management for patients suffering from various neuropathic and inflammatory conditions.